APL-2301
Phase 1- Indications
- Acinetobacter baumannii infections, Carbapenem-resistant Acinetobacter baumannii infections
Company intelligence / Profile preview
MetCura Pharmaceuticals
Unknown, South Australia, Australialinkedin.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
APL-2301 (formerly ASN-1733/MET-102) was approved for Phase I clinical trials in Australia for the treatment of Acinetobacter baumannii infections. Preclinical research data has demonstrated good activity against various clinical isolates of Acinetobacter baumannii, particularly against CRAB[5][10].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on MetCura Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MetCura Pharmaceuticals.